Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTABACT
2023-510191-31-00Phase 3Withdrawn
- Sponsor
- CHRU Tours
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of fosfomycin and trimethoprim + sulfamethoxazole in benign prostatic hyperplasia (BPH) and urinary tract infection (UTI) (2 arms), sponsored by CHRU Tours. Planned start Feb 2025; status: withdrawn.
02
Drugs
fosfomycintrimethoprim + sulfamethoxazole
03
Conditions
benign prostatic hyperplasia (BPH)urinary tract infection (UTI)
Beyond the preview
Go deeper on 2023-510191-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510191-31-00.